# "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"

> **NCT01641406** · PHASE2 · UNKNOWN · sponsor: **Auxilio Mutuo Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Infiltrating Duct and Lobular Carcinoma In Situ
- Invasive Lobular Breast Carcinoma
- Inflammatory Breast Carcinoma

## Interventions

- **DRUG:** Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
- **DRUG:** Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
- **DRUG:** Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab

## Key facts

- **NCT ID:** NCT01641406
- **Lead sponsor:** Auxilio Mutuo Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2012-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641406, ""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01641406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*